References
- Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. In: Powell MF, Newman MJ, Editors Vaccine design: The subunit and adjuvant approach. Plenum Press; New York: 1995. p. 141-228
- Valenzuela P, Medina A, Rutter WJ, et al. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982;298:347-50
- Edelman R, Tacket CO. Adjuvants. Int Rev Immunol 1990;7:51-66
- Fox CB, Haensler J. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev Vaccines 2013;12:747-58
- Food and Drug Administration. FDA approves first adjuvanted vaccine for prevention of H5N1 avian influenza. US Food and Drug Administration, Silver Spring, MD, USA; 2013
- GlaxoSmithKline. GSK announces EU regulatory submission for malaria vaccine candidate RTS,S. GlaxoSmithKline, London, UK: 2014
- Novartis. Novartis receives in approval in Canada for Fluad PediatricTM, the first vaccine designed to help better protect infants from seasonal flu. Novartis, Dorval, QC: 2015
- GlaxoSmithKline. Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint. GlaxoSmithKline, London, UK: 2014
- Kester KE, Cummings JF, Ofori-Anyinam O, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009;200:337-46
- RTS/S-Clinical-Trials-Partnership. A Phase III trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012;367:2284-95
- Vesikari T, Knuf M, Wutzler P, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011;365:1406-16
- Knuf M, Leroux-Roels G, Rümke HC, et al. Immunogenicity and Tolerability of an MF59-adjuvanted, Egg-derived, A/H1N1 Pandemic Influenza Vaccine in Children 6–35 Months of Age. Pediatr Infect Dis J 2014;33:e320-9
- Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009;21:317-37
- Wu TY, Singh M, Miller AT, et al. Rational design of small molecules as vaccine adjuvants. Sci Trans Med 2014;6:263ra160
- Dynavax. HEPLISAV-BTM Hepatitis B Vaccine
- Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvanted H1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 2012;7:e33536
- Vaarala O, Vuorela A, Partinen M, et al. Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk. PLoS One 2014;9:e114361
- Food and Drug Administration. A (H7N9) VLP antigen dose-ranging study with matrix-M1™ Adjuvant: NCT02078674. US Food and Drug Administration, Silver Spring, MD, USA; 2015
- Food and Drug Administration. Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine: NCT0199156. US Food and Drug Administration, Silver Spring, MD, USA; 2015
- Brito LA, Malyala P, O’Hagan DT. Vaccine adjuvant formulations: A pharmaceutical perspective. Sem Immunol 2013;25:130-45